FDA Declines to Approve Pegfilgrastim Biosimilar

Share this content:
The U.S. Food and Drug Administration (FDA) denied approval to the biosimilar pegfilgrastim candidate developed by Sandoz.
The U.S. Food and Drug Administration (FDA) denied approval to the biosimilar pegfilgrastim candidate developed by Sandoz.

The U.S. Food and Drug Administration (FDA) denied approval to the biosimilar pegfilgrastim candidate developed by Sandoz, a division of Novartis, according to a press release from Novartis.1

Pegfilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of infection for patients receiving myelosuppressive anti-cancer agents.

"Sandoz received a complete response letter from the FDA for biosimilar pegfilgrastim candidate (Neulasta)," Novartis said in a statement. "We are working with the agency to address remaining questions."

RELATED: Online Resource Center on Biosimilars Launched

The application was based on findings from 3 pivotal clinical trials, including 1 pharmacokinetic and pharmacodynamic study in healthy volunteers, and 2 comparative efficacy and safety studies of patients with breast cancer.

In March 2015, the FDA approved Sandoz's filgrastim-sndz, the first biosimilar product approved in the United States.                                      

Reference

  1. Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects. Novartis website. https://www.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact. Updated July 19, 2016. Accessed July 21, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs